Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR1 | P30872 | 1/20 | 0.34 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.34 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.34 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.34 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19760422 | 1.00 | SSTR1 (0.34) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL12416160 | 0.86 | — | — | |
| SCHEMBL19051013 | 0.86 | — | — | |
| SCHEMBL19760424 | 0.86 | — | — | |
| SCHEMBL19078924 | 0.86 | — | — | |
| SCHEMBL10366417 | 0.82 | FGF1 (0.31) | — | |
| SCHEMBL25594520 | 0.82 | FGF1 (0.33) | — | |
| SCHEMBL18294595 | 0.82 | FGF1 (0.33) | — | |
| SCHEMBL19051014 | 0.82 | FGF1 (0.33) | — | |
| SCHEMBL25594518 | 0.82 | FGF1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240209368-A1 | EXTRACELLULAR VESICLE COMPOSITIONS | LONZA SALES AG (CH) | 2024-06-27 | — | — | US | disclosed |
| US-20240018519-A1 | Stabilized saRNA Compositions and Methods of Use | MINA THERAPEUTICS LIMITED (GB) | 2024-01-18 | — | — | US | disclosed |
| US-20230399643-A1 | COMPLEMENT COMPONENT C1S INHIBITORS FOR TREATING A NEUROLOGICAL DISEASE, AND RELATED COMPOSITIONS, SYSTEMS AND METHODS OF USING SAME | GENENTECH, INC. (US) | 2023-12-14 | — | — | US | disclosed |
| US-20230364127-A1 | EXTRACELLULAR VESICLE-ASO CONSTRUCTS TARGETING STAT6 | CODIAK BIOSCIENCES, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230331837-A1 | OLIGONUCLEOTIDES FOR REDUCTION OF PD-L1 EXPRESSION | HOFFMANN-LA ROCHE INC. (US) | 2023-10-19 | — | — | US | disclosed |
| US-20230323362-A1 | COMPLEMENT COMPONENT C1R INHIBITORS FOR TREATING A NEUROLOGICAL DISEASE, AND RELATED COMPOSITIONS, SYSTEMS AND METHODS OF USING SAME | GENENTECH, INC. (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230323421-A1 | OLIGONUCLEOTIDES TARGETING XBP1 | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2023-10-12 | — | — | US | disclosed |
| US-20230313189-A1 | COMPLEMENT COMPONENT 4 INHIBITORS FOR TREATING NEUROLOGICAL DISEASES, AND RELATED COMPOSITONS, SYSTEMS AND METHODS OF USING SAME | GENENTECH, INC. (US) | 2023-10-05 | — | — | US | disclosed |
| US-20230302036-A1 | COMPOSITIONS FOR TREATMENT OF SPINAL MUSCULAR ATROPHY | UNIVERSIDAD DE BUENOS AIRES (AR) | 2023-09-28 | — | — | US | disclosed |
| US-20230304089-A1 | IN VITRO NEPHROTOXICITY SCREENING ASSAY | HOFFMANN-LA ROCHE INC. | 2023-09-28 | — | — | US | disclosed |
| US-11753640-B2 | Oligonucleotides for modulating Tau expression | HOFFMANN-LA ROCHE INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11732262-B2 | Use of FUBP1 inhibitors for treating hepatitis B virus infection | UNIVERSITE CLAUDE BERNARD LYON I (FR) | 2023-08-22 | — | — | US | disclosed |
| US-20230241089-A1 | STING AGONIST COMPRISING EXOSOMES FOR TREATING NEUROIMMUNOLOGICAL DISORDERS | CODIAK BIOSCIENCES, INC. (US) | 2023-08-03 | — | — | US | disclosed |
| US-20230212572-A1 | Guanosine Analogues for Use in Therapeutics Polynucleotides | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2023-07-06 | — | — | US | disclosed |
| US-20230210887-A1 | NUCLEIC ACID MOLECULES FOR REDUCTION OF PAPD5 OR PAPD7 MRNA FOR TREATING HEPATITIS B INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2023-07-06 | — | — | US | disclosed |
| US-20230193269-A1 | OLIGONUCLEOTIDES FOR SPLICE MODULATION OF CARD9 | BOEHRINGER INGELHEIM INT (DE) | 2023-06-22 | — | — | US | disclosed |
| US-20230183692-A1 | USE OF SEPT9 INHIBITORS FOR TREATING HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. | 2023-06-15 | — | — | US | disclosed |
| US-20170283496-A1 | OLIGONUCLEOTIDES FOR REDUCTION OF PD-L1 EXPRESSION | HOFFMANN-LA ROCHE INC. | 2017-10-05 | — | — | US | disclosed |
| US-20170191064-A1 | OLIGONUCLEOTIDES FOR INDUCING PATERNAL UBE3A EXPRESSION | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230302036-A1 | COMPOSITIONS FOR TREATMENT OF SPINAL MUSCULAR ATROPHY | SMN1; SMN2, HDAC7, SNRPB2 | SSTR1 692/4885SSTR2 532/4885SSTR4 1143/4885 |
| US-20230241089-A1 | STING AGONIST COMPRISING EXOSOMES FOR TREATING NEUROIMMUNOLOGICAL DISORDERS | STING1, TLR9, TBK1 | SSTR1 2004/4885SSTR2 1994/4885SSTR4 2376/4885 |
| US-20240209368-A1 | EXTRACELLULAR VESICLE COMPOSITIONS | EXOSC5, EXOSC9, EXOSC4 | SSTR1 1703/4885SSTR2 2022/4885SSTR4 2192/4885 |
| US-20170283496-A1 | OLIGONUCLEOTIDES FOR REDUCTION OF PD-L1 EXPRESSION | CD274, PDCD1LG2, PDCD1 | SSTR1 1592/4885SSTR2 2172/4885SSTR4 954/4885 |
| US-20230323421-A1 | OLIGONUCLEOTIDES TARGETING XBP1 | XBP1, HSPA5, UPF1 | SSTR1 2821/4885SSTR2 3389/4885SSTR4 2760/4885 |
| US-11732262-B2 | Use of FUBP1 inhibitors for treating hepatitis B virus infection | FUBP1, FUBP3, SERBP1 | SSTR1 4585/4885SSTR2 4612/4885SSTR4 4586/4885 |
| US-20230183692-A1 | USE OF SEPT9 INHIBITORS FOR TREATING HEPATITIS B VIRUS INFECTION | SEPTIN9, SEPTIN7, SEPTIN2 | SSTR1 3404/4885SSTR2 3473/4885SSTR4 2806/4885 |
| US-20230210887-A1 | NUCLEIC ACID MOLECULES FOR REDUCTION OF PAPD5 OR PAPD7 MRNA FOR TREATING HEPATITIS B INFECTION | BCDIN3D, ZC3HAV1, HAVCR2 | SSTR1 4853/4885SSTR2 4858/4885SSTR4 4823/4885 |
| US-20230193269-A1 | OLIGONUCLEOTIDES FOR SPLICE MODULATION OF CARD9 | CARD19, TLR9, NOD2 | SSTR1 3705/4885SSTR2 4171/4885SSTR4 2956/4885 |
| US-20230331837-A1 | OLIGONUCLEOTIDES FOR REDUCTION OF PD-L1 EXPRESSION | CD274, PDCD1LG2, PDCD1 | SSTR1 1592/4885SSTR2 2172/4885SSTR4 954/4885 |
| US-20230364127-A1 | EXTRACELLULAR VESICLE-ASO CONSTRUCTS TARGETING STAT6 | STAT6, STAT1, STAT3 | SSTR1 1650/4885SSTR2 1831/4885SSTR4 1147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.